Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955310 | 0.85 | KCNJ1 (0.35) | IL1RNERAP2ERAP1KCNJ1PIK3CD | |
| SCHEMBL31039569 | 0.81 | IL1RN (0.37) | IL1RNERAP2ERAP1WNT3ATNKS2 | |
| SCHEMBL21954990 | 0.81 | IL1RN (0.37) | IL1RNERAP2ERAP1WNT3ATNKS2 | |
| SCHEMBL29711059 | 0.79 | IL1RN (0.36) | IL1RNERAP2ERAP1KCNJ1PRKDC | |
| SCHEMBL13249025 | 0.76 | IL1RN (0.34) | IL1RNERAP2ERAP1PRKDCERN1 | |
| SCHEMBL11813225 | 0.76 | IL1RN (0.34) | IL1RNERAP2ERAP1PRKDCERN1 | |
| SCHEMBL28992944 | 0.74 | KCNJ1 (0.33) | KCNJ1PRKDCERN1 | |
| SCHEMBL21955154 | 0.73 | IL1RN (0.36) | IL1RNERAP2ERAP1WNT3ATNKS2 | |
| SCHEMBL33526079 | 0.73 | IL1RN (0.33) | IL1RNERAP2ERAP1WNT3ATNKS2 | |
| SCHEMBL28632223 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3873897-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-112996786-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | IL1RN 88/4885ERAP2 3283/4885ERAP1 2796/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | IL1RN 88/4885ERAP2 3283/4885ERAP1 2796/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | IL1RN 88/4885ERAP2 3283/4885ERAP1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.